Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 1

Status

Completed 64Terminated 19Unknown 13Active not recruiting 10Recruiting 5Withdrawn 3Not yet recruiting 3

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Lung Neoplasms 7Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Squamous Cell Carcinoma 3Cholangiocarcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Ovarian Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Neoplasms, Basal Cell 1Muscle-Invasive Bladder Carcinoma 1Metastatic Pancreatic Ductal Adenocarcinoma 1Metastatic Pancreatic Adenocarcinoma 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Pancreatic Cancer 1

Interventions

Fulvestrant 60Capecitabine 47Trastuzumab 46Letrozole 45pembrolizumab 42Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37abemaciclib 36pertuzumab 34Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Surveys and Questionnaires 26Docetaxel 26Tamoxifen 25Anastrozole 25exemestane 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT06312176 2026-05-22

MK-2870-010

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,200 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT07060807 2026-05-22

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,000 enrolled
Breast

Breast Neoplasms

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
53 enrolled
Breast

Breast Neoplasms

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

M.D. Anderson Cancer Center

Phase 1 Recruiting
43 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Recruiting
72 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡